|
|
|
|
Archives
|
Entry
|
Author
|
Date
|
Location
|
|
Boston Xconomists and Area Innovators Gather for Special Xconomy Event: The Photos
|
Erin Kutz |
10/13/11 |
Boston
|
|
Cocrystal, Led by Icos Vets and Stanford Nobelist, Hunts for Next Big Thing for Hepatitis C
|
Luke Timmerman |
09/22/11 |
Seattle
|
|
Stirring the Pot Once in a While Doesn’t Hurt, and It Could Help Biotech Break its Malaise
|
Luke Timmerman |
09/19/11 |
National
|
|
Cocrystal Discovery Snags $7.5M in Hepatitis C Collaboration With Teva
|
Luke Timmerman |
09/15/11 |
Seattle
|
|
Dramatic Changes in Hepatitis C Treatment Expected to Continue
|
Steve Worland |
09/06/11 |
San Diego
|
|
Fearless Fantasy Football, Uh, I Mean Biotech, Predictions for the Season Ahead
|
Luke Timmerman |
09/06/11 |
National
|
|
The Fall of Pfizer: How Big is Too Big for Pharma Innovation?
|
Luke Timmerman |
08/29/11 |
National
|
|
Xconomist of the Week: Tony Coles’ Journey from Mass General Doctor to SF Biotech CEO
|
Luke Timmerman |
08/18/11 |
National
|
|
Dendreon Wounds Are Self-Inflicted, Not the Start of a Biotech Industry Virus
|
Luke Timmerman |
08/08/11 |
National
|
|
Vertex Smashes Wall Street Sales Expectations In Hepatitis C Drug Debut
|
Luke Timmerman |
07/28/11 |
Boston
|
|
Stop the M&A Obsession: Biotech Needs More Companies to Stay Independent
|
Luke Timmerman |
07/18/11 |
National
|
|
aTyr Pharma Looks to Strike Balance Between Nonprofits, and Really Big For-Profits
|
Luke Timmerman |
07/06/11 |
San Diego
|
|
Brightcove Moving to Boston, Looks to Hire
|
Gregory T. Huang |
07/05/11 |
Boston
|
|
Seattle Genetics, On the Verge of Going Commercial, Seeks to Keep Its Scientific Soul
|
Luke Timmerman |
07/05/11 |
Seattle
|
|
Biogen Eyes Cambridge Move, Vertex Licenses Alios Drugs, Concert Nabs GSK Payment, & More Boston-Area Life Sciences News
|
Erin Kutz |
06/24/11 |
Boston
|
|
Vertex Pays $60M for Alios Drugs, PKE Acquires Dexela, AisleBuyer Grabs $7.5M, & More Boston-Area Deals News
|
Erin Kutz |
06/15/11 |
Boston
|
|
Vertex Adds New HepC Drugs for $60M
|
Luke Timmerman |
06/13/11 |
Boston
|
|
Orexigen Halts U.S. Work on Weight Loss Drug, Illumina Cuts Price for Sequencing Patient Genomes, Ambit Pulls IPO, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
06/09/11 |
San Diego
|
|
The Quest For Biotech Independence: Maybe It Isn’t So Quixotic After All
|
Luke Timmerman |
06/06/11 |
National
|
|
Vertex Gets FDA OK, Alnylam Plans For ASCO, Biogen Drug Advances in Europe, & More Boston-Area Life Sciences News
|
Erin Kutz |
05/27/11 |
Boston
|
|
Vertex, On Deadline, Wins FDA Approval for Hepatitis C Drug
|
Luke Timmerman |
05/23/11 |
Boston
|
|
How to Make Money in Biotech With No Hope of Going Public, Slim Odds of Getting Acquired
|
Luke Timmerman |
05/23/11 |
National
|
|
PerkinElmer Buys Labtronics, Vertex Rival Merck Partners with Genentech, ThermoFisher Acquires Phadia, & More Boston-Area Life Sciences News
|
Erin Kutz |
05/20/11 |
Boston
|
|
Merck, Genentech Team Up on Hepatitis C Drugs, Raising Ante in Vertex Rivalry
|
Luke Timmerman |
05/17/11 |
New York
|
|
Vertex Signs Boston Lease
|
Luke Timmerman |
05/05/11 |
Boston
|
|
New Health IT Startup Targets Military Programs, Allylix Sniffs New Market for Nootkatone, Biocept Builds Team, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
05/05/11 |
San Diego
|
|
FDA Panel OKs Vertex Drug, Dyax Works With FivePrime, Genzyme Amends Anika Lawsuit, & More Boston-Area Life Sciences News
|
Erin Kutz |
04/29/11 |
Boston
|
|
Vertex Wins FDA Panel’s Recommendation for New Hepatitis C Drug
|
Luke Timmerman |
04/28/11 |
Boston
|
|
FDA Panel Meets Today on Vertex HepC Drug
|
Ryan McBride |
04/28/11 |
Boston
|
|
FDA Says Vertex Drug a Wee Bit More Effective Than Advertised; Stock Climbs
|
Luke Timmerman |
04/26/11 |
Boston
|
|
Page 2 of
8 |
« previous page · next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.